Corbevax booster for heterologous first has been approved by the Centre.Last month the National Technical Advisory Group on Immunisation (NTAGI) recommended Biological E’s CORBEVAX as a heterologous booster for adults above 18 yrs old. Read more on Dynamite News:
Union Health Minister Mansukh Mandaviya on Thursday said that the vaccination for the children of 5-12 years will soon start after the recommendation of National Technical Advisory Group of Immunization (NTAGI). Read further on Dynamite News:
DCGI (Drugs Controller General of India) gives restricted emergency use authorisation to BharatBiotech’s Covaxin for children between the age of 6-12 years. More details on Dynamite News:
The Drugs Controller General of India (DCGI) on Thursday granted conditional regular market approval for COVID-19 vaccines Covaxin and Covishield for restricted use in emergency situations in the adult population.
The World Health Organisation (WHO) on Wednesday granted approval for Emergency Use Listing (EUL) for Bharat Biotech’s COVID-19 vaccine, Covaxin. Full story
Vaccine maker Bharat Biotech on Wednesday said the Central Drugs Standard Control Organisation (CDSCO) has approved the extension of shelf life of its COVID-19 vaccine Covaxin up to 12 months from the date of manufacture.
Union Health Minister Mansukh Mandaviya on Thursday met World Health Organization (WHO) Chief Scientist Dr Soumya Swaminathan and held a discussion over the world body’s approval of Bharat Biotech’s Covaxin.
Bharat Biotech’s COVID-19 vaccine Covaxin has shown less reduction in ‘neutralizing activity’ while comparing with Delta and Delta AY.1 (Delta plus) variants in those who are fully vaccinated with the vaccine according to a study by the Indian Council of Medical Research-National Institute of Virology (NIV).
Trials for Bharat Biotech’s Covid-19 vaccine Covaxin on children are underway and results are expected to be released by September, All India Institute of Medical Sciences (AIIMS) director Randeep Guleria informed.
English
English
English
